IRX 4310

Drug Profile

IRX 4310

Alternative Names: AGN-194310; AGN-4310; ALRT-4310; LGD-4310; NRX-4310

Latest Information Update: 19 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan; Ligand Pharmaceuticals
  • Developer Allergan; Io Therapeutics
  • Class Antipsoriatics; Benzoic acids; Thiophenes
  • Mechanism of Action Retinoic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neutropenia
  • Discontinued Acne; Atopic dermatitis; Psoriasis; Xerostomia

Most Recent Events

  • 19 Apr 2016 No recent reports on development identified - Preclinical for Neutropenia (Chemotherapy-induced) in USA (PO)
  • 06 Oct 2011 Discontinued - Phase-II for Acne in United Kingdom (unspecified route)
  • 06 Oct 2011 Discontinued - Phase-III for Atopic dermatitis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top